Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

Pharmaceutical Technology

FEBRUARY 27, 2023

Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Pfizer overview Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals.

Hormones 100

Hormones Contract Manufacturing Manufacturing Development 100

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development 72

Development Hormones Drugs Trials 72

XTalks

NOVEMBER 9, 2023

XTALKS WEBINAR: The Evolution of the Cardiovascular Clinical Development Landscape and Potential Role of GLP-1 RAs Live and On-Demand: Wednesday, December 6, 2023, at 11am EST (4pm GMT/UK) Register for this free webinar to learn about successful study outcomes in developing GLP1s to new therapeutic areas within cardiovascular medicine and more. “In

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

Drug Discovery World

JUNE 1, 2023

8 Last, but not least, in April 2023, BioNTech signed a $170 million licensing deal with Duality Biologics, a Chinese clinical-stage biotech company focusing on the discovery and development of next generation ADC therapeutics to treat patients with cancer and autoimmune diseases.

Antibody 98

Antibody Marketing Drugs Licensing 98

The Pharma Data

DECEMBER 9, 2020

HALIX – Based in The Netherlands, HALIX BV and AstraZeneca forged an agreement to support large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine. Amolyt has also acquired an option to license the identified candidates for future clinical development.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

OCTOBER 14, 2020

FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from two randomized, controlled trials (HARMONY CTP and HARMONY 1) from the clinical development program for WAKIX. WAKIX may reduce the effectiveness of hormonal contraceptives. Use in Specific Populations.

FDA Approval 52

FDA Approval Hormones Production Drugs 52

The Pharma Data

DECEMBER 15, 2020

Contribution of these robust data sets from industry led trials is critical to TOMI-T1D’s work in developing innovative and quantitative tools that can facilitate clinical development efforts and be endorsed by regulators for future use by the pharmaceutical industry to optimize the design of future clinical trials.

Development 40

Development Insulin Drugs Clinical Trials 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JANUARY 10, 2021

By the end of the year, we expect to have five independent TransCon product candidates in clinical development leveraging TransCon technologies through our algorithm for product innovation. Pipeline Updates. •. ?. . . . . ?.

Hormones 40

Hormones Clinical Development Clinical Trials Clinical Trials 40

Roots Analysis

MAY 21, 2024

This allows targeted protein degradation approaches to target “undruggable” proteins, such as transcription factors, non-enzymatic proteins and scaffolding proteins, widening the scope for the clinical development of next generation therapeutic modalities.

Protein 40

Protein Marketing Development Antibody 40

Pharmaceutical Technology

MARCH 2, 2023

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bile Duct Cancer (Cholangiocarcinoma). It was also under development for the treatment of nasopharyngeal cancer and homologous-recombination deficient (HRD) metastatic hormone refractory prostate cancer.

FDA Approval 100

FDA Approval Containment Development Genome 100

The Pharma Data

OCTOBER 26, 2020

. As monotherapy for the treatment of BRCA 1/2 metastatic castration-resistant prostate cancer (mCRPC) patients who have progressed following a prior therapy that included a new hormonal agent based on the Phase 3 PROfound trial. Research and development expenses were $3.4 Canada and Europe. Organon & Co.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

MARCH 17, 2021

Verzenio is Lilly’s first solid oral dosage form to be made using a faster, more efficient process known as continuous manufacturing. Continuous manufacturing is a new and advanced type of manufacturing within the pharmaceutical industry, and Lilly is one of the first companies to use this technology. INDICATION.

HR 52

HR Trials In-Vitro Manufacturing 52

The Pharma Data

OCTOBER 14, 2020

The AOP Orphan Group manufactures 80% of its drugs in Europe and has more than 20 subsidiaries and representative offices across the whole of Europe as well as in the United Arab Emirates and Israel. The funds will be used to bring Ori’s innovative manufacturing platform to the market. Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

The Pharma Data

JUNE 28, 2021

GIP is a hormone that may complement the effects of GLP-1. The SURPASS phase 3 global clinical development program for tirzepatide has enrolled more than 19,000 people with type 2 diabetes across 10 clinical trials, five of which are global registration studies. mg for four weeks and then reached the final dose of 1 mg.

Insulin 52

Insulin Clinical Trials Clinical Trials Hormones 52

The Pharma Data

DECEMBER 2, 2020

The new plant will as a first priority produce recombinant GAD65, the active pharmaceutical ingredient in the therapeutic diabetes vaccine Diamyd ® currently in late-stage clinical development.

Production 52

Production Insulin Vaccination Vaccine 52

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246

The Pharma Data

DECEMBER 27, 2020

For patients using hormonal contraception associated with a risk of thrombosis, consider an alternative method of effective contraception during treatment. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics.

Production 52

Production Drugs Clinical Trials Clinical Trials 52